Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.80USD
−4.55 MUSD
3.21 MUSD
About IMMURON LIMITED
Sector
CEO
Steven Lydeamore
Headquarters
Blackburn North
Website
Founded
1994
FIGI
BBG000LZD9X8
Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. Its proprietary technology is based on polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum. This technology can be used to target viruses or bacteria and neutralize the toxins they produce on mucosal surfaces. It operates through the Research and Development, and Hyperimmune Products segments. The Research and Development segment includes projects performed in Australia and United States. The Hyperimmune Products segment is composed of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994, and is headquartered in Carlton, Australia.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.